Stocks · News reference
Maxim Group analyst Jason McCarthy initiates coverage on Telomir Pharmaceuticals (NASDAQ:TELO) with a Buy rating and announces Price Target of $4.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6
Filed: 2026-10-06 AccNo: 0001493152-26-045860 Size: 918 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits